logo
Plus   Neg
Share
Email

Novartis Commits To Increase Patient Reach; Enhances Full Carbon Neutrality Target

Novartis said it has committed to increase patient reach with its strategic medicines by at least 200% by 2025, as part of its ambition to expand access to medicines in low- and middle-income countries or LMICs.

In addition, the company plans to increase patient reach of its global health flagship programs in Leprosy, Malaria, Chagas Disease and Sickle Cell Disease by at least 50% over the same time period.

The company estimates achievement of those targets to result in a potential reach of over 23 million patients across both initiatives.

The company said it also further strengthened its carbon neutrality target to aim for full carbon neutrality across its supply chain by 2030, in addition to its already stated target for carbon neutrality in its own operations by 2025.

In addition, Novartis said that it has collaborated with the African Union initiated Africa Medical Supplies Platform to support the supply of medicines from the Novartis COVID-19 Pandemic Response Portfolio. The portfolio of 15 medicines, including Dexamethasone, for symptomatic treatment of COVID-19 for LMICs was launched in July 2020 and is provided through Sandoz, the generics and biosimilar division of Novartis.

The company noted that it completed enrollment in CAN-COVID Phase III clinical trial, studying canakinumab in patients with COVID-19 pneumonia, with an expected readout in Q4 2020. Novartis also continues a Phase III clinical trial to evaluate the use of ruxolitinib in COVID-19 patients with a severe immune reaction.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform U.S. airline Delta Air Lines, Inc. and its Italian codeshare partner Alitalia are planning to launch quarantine-free, COVID-free flights between U.S. and Europe through new testing protocols, starting in December. In a statement, Delta said it has signed deals with airports and governments eliminating quarantine requirements on COVID-tested flights connecting Atlanta and Rome.
Follow RTT